Relmada Therapeutics (RLMD) Retained Earnings (2012 - 2026)
Relmada Therapeutics (RLMD) reported Retained Earnings of -$717.3 million for Q1 2026, down 8.94% year-over-year from -$787.8 million in Q1 2025, and down 2.73% quarter-over-quarter from -$698.3 million in Q4 2025.
Relmada Therapeutics (RLMD) Retained Earnings (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 15 years of Retained Earnings data on file, last reported at -$717.3 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$717.3 million, down 8.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$717.3 million (down 8.94% YoY), and the FY2025 annual result was -$698.3 million, down 8.95% from the prior year.
- Retained Earnings retreated to -$717.3 million in Q1 2026 per RLMD's latest filing, from -$698.3 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$344.8 million in Q1 2022 and troughed at -$717.3 million in Q1 2026.
- A 5-year average of -$563.6 million and a median of -$582.7 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings tumbled 71.1% in 2022, then retreated 8.94% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$462.1 million in 2022, then dropped by 21.38% to -$560.9 million in 2023, then slipped by 14.26% to -$640.9 million in 2024, then retreated by 8.95% to -$698.3 million in 2025, then dropped by 2.73% to -$717.3 million in 2026.
- Business Quant data shows RLMD's Retained Earnings at -$717.3 million in Q1 2026, -$698.3 million in Q4 2025, and -$678.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | -717.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -717.32 Mn |
| Dec 31, 2025 | -698.27 Mn |
| Sep 30, 2025 | -678.40 Mn |
| Jun 30, 2025 | -668.31 Mn |
| Mar 31, 2025 | -658.44 Mn |
| Dec 31, 2024 | -640.88 Mn |
| Sep 30, 2024 | -622.22 Mn |
| Jun 30, 2024 | -600.50 Mn |
| Mar 31, 2024 | -582.73 Mn |
| Dec 31, 2023 | -560.90 Mn |
| Sep 30, 2023 | -535.74 Mn |
| Jun 30, 2023 | -513.74 Mn |
| Mar 31, 2023 | -488.43 Mn |
| Dec 31, 2022 | -462.11 Mn |
| Sep 30, 2022 | -424.17 Mn |
| Jun 30, 2022 | -384.75 Mn |
| Mar 31, 2022 | -344.81 Mn |
| Dec 31, 2021 | -305.07 Mn |
| Sep 30, 2021 | -270.69 Mn |
| Jun 30, 2021 | -228.08 Mn |